NASH Phase II Interim Analysis Reveals Improvement in Liver Enzymes (AST and ALT) with Good Safety and Tolerability
Immuron Limited - American Depositary Shares (IMRN)
US:NASDAQ Investor Relations:
immuron.com/investor-centre/business-overview
Company Research
Source: GlobeNewswire
MELBOURNE, Australia, July 10, 2017 (GLOBE NEWSWIRE) -- Australian biopharmaceutical company, Immuron Limited (ASX:IMC) (NASDAQ:IMRN), is pleased to announce safety and efficacy results of the interim analysis of its ongoing IMM-124E Phase II study in NASH. The objectives of this analysis was to establish the safety of the compound and to provide a preliminary read on efficacy signals. The NASH Phase II trial has enrolled 133 patients with the top-line results expected in 4Q2017. The pre-planned analysis was triggered when 80 subjects completed treatment. The demographics of the population analyzed in the interim analysis were balanced in all three groups (placebo, low dose -600mg- and high dose -1200mg-) including sex, race, age, height, weight, BMIs, HbA1c and baseline hepatic fat fraction (HFF). Highlights from the interim analysis are as follows: IMM-124E was safe and there were no safety signals when compared to placebo.The treatment was well tolerated and no subjects di
Show less
Read more
Impact Snapshot
Event Time:
IMRN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
IMRN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
IMRN alerts
High impacting Immuron Limited - American Depositary Shares news events
Weekly update
A roundup of the hottest topics
IMRN
News
- Immuron to host Live Virtual Event [Yahoo! Finance]Yahoo! Finance
- Immuron to host Live Virtual EventGlobeNewswire
- Immuron Travelan® sales continued strong growthGlobeNewswire
- We're Not Very Worried About Immuron's (ASX:IMC) Cash Burn Rate [Yahoo! Finance]Yahoo! Finance
- Immuron Presentation Australian Biologics Festival 2024GlobeNewswire
IMRN
Sec Filings
- 4/23/24 - Form 6-K
- 4/15/24 - Form 6-K
- 4/10/24 - Form 6-K
- IMRN's page on the SEC website